Home › Lymphoma › Texas › Houston
Lymphoma clinical trials in Houston, TX
34 studies for Lymphoma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RecruitingPhase 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
- Texas Children's Hospital, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
- Baylor College of Medicine, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecruitingPhase 1
- University of Texas - MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RecruitingPhase 1/2
- Research Site, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RecruitingPhase 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RecruitingPhase 3
- Research Site, Houston
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 1
- Baylor College of Medicine, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RecruitingPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RecruitingPhase 1/2
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
- MD Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
RecruitingPhase 1
- UT MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
RecruitingPhase 1
- The University of Texas M D Anderson Cancer Center, Houston
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
RecruitingPhase 1
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
RecruitingPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
RecruitingPhase 1/2
- Dren Investigational Site, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
RecruitingObservational study
- M D Anderson Cancer Center, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Recruiting
- MD Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingPhase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RecruitingPhase 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
About Lymphoma
Lymphoma is a cancer affecting the immune system. Hodgkins Lymphoma and Non Hodgkins Lymphoma are types of lymphoma. Learn about symptoms and treatments.
More about Lymphoma on MedlinePlus
Lymphoma trials in other cities
- Boston, MA33 studies
- New York City, NY33 studies
- Washington, DC23 studies
- Baldwin Park, CA21 studies
- Chicago, IL20 studies
- Durham, NC17 studies
- St. Louis, MO15 studies
- Philadelphia, PA15 studies
- Cleveland, OH14 studies
- Edison, NJ12 studies
- Atlanta, GA12 studies
- Seattle, WA12 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)121 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia85 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer61 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.